Brand specific responses to smokeless tobacco in a rat lip canal model

Journal of Oral Pathology and Medicine

Volumn 39, Issue 6, 2010, Pages 453-459

  Schwartz, Joel L ^a,b   Brunnemann, Klaus D ^c   Adami, Alexander J ^a   Panda, Suchismita ^a   Gordon, Sara C ^a   Hoffmann, Dietrich ^b   Adami, Guy R ^a  

^a UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

^b AMERICAN HEALTH FOUNDATION   (United States)

^c NEW YORK MEDICAL COLLEGE   (United States)

Author keywords

dysplasia; lip canal; nitrosamines; smokeless tobacco; squamous cell carcinoma

Indexed keywords

NICOTINE; NITROSAMINE; PROTEIN P16; CYCLINE; TUMOR PROTEIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL CYCLE M PHASE; CELL CYCLE S PHASE; CELL PROLIFERATION; CONTROLLED STUDY; DISEASE COURSE; DYSPLASIA; HISTOPATHOLOGY; KERATOSIS; LIP; LONG TERM EXPOSURE; MOISTURE; MOUTH MUCOSA; NONHUMAN; PH; PRIORITY JOURNAL; PROTEIN DEPLETION; PROTEIN EXPRESSION; RAT; SMOKELESS TOBACCO; ANIMAL; DRUG EFFECTS; ENZYME IMMUNOASSAY; SPRAGUE DAWLEY RAT;

ANIMALS; CELL PROLIFERATION; HYDROGEN-ION CONCENTRATION; IMMUNOENZYME TECHNIQUES; LIP; MOUTH MUCOSA; NEOPLASM PROTEINS; NICOTINE; NITROSAMINES; PROLIFERATING CELL NUCLEAR ANTIGEN; RATS; RATS, SPRAGUE-DAWLEY; TOBACCO, SMOKELESS;

EID: 77954361465     PISSN: 09042512     EISSN: 16000714     Source Type: Journal    
DOI: 10.1111/j.1600-0714.2010.00892.x     Document Type: Article

References (38)

1. Boffetta P, Hecht S, Gray N, Gupta P, Straif K. Smokeless tobacco and cancer. Lancet Oncol 2008 9 : 667 675.
2. Warnakulasuriya KA, Ralhan R. Clinical, pathological, cellular and molecular lesions caused by oral smokeless tobacco - a review. J Oral Pathol Med 2007 36 : 63 77.
3. Cogliano V, Straif K, Baan R, Grosse Y, Secretan B, El Ghissassi F. Smokeless tobacco and tobacco-related nitrosamines. Lancet Oncol 2004 5 : 708.
4. Levy DT, Mumford EA, Cummings KM, et al. The relative risks of a low-nitrosamine smokeless tobacco product compared with smoking cigarettes: estimates of a panel of experts. Cancer Epidemiol Biomarkers Prev 2004 13 : 2035 2042.
5. Roosaar A, Johansson AL, Sandborgh-Englund G, Axell T, Nyren O. Cancer and mortality among users and nonusers of snus. Int J Cancer 2008 123 : 168 173.
6. Johansson SL, Saidi J, Osterdahl BG, Smith RA. Promoting effect of snuff in rats initiated by 4-nitroquinoline-N-oxide or 7,12-dimethylbenz(a)anthracene. Cancer Res 1991 51 : 4388 4394.
7. Grasso P, Mann AH. Smokeless tobacco and oral cancer: an assessment of evidence derived from laboratory animals. Food Chem Toxicol 1998 36 : 1015 1029.
8. Hecht SS, Rivenson A, Braley J, DiBello J, Adams JD, Hoffmann D. Induction of oral cavity tumors in F344 rats by tobacco-specific nitrosamines and snuff. Cancer Res 1986 46 : 4162 4166.
9. Padma PR, Lalitha VS, Amonkar AJ, Bhide SV. Carcinogenicity studies on the two tobacco-specific N-nitrosamines, N′-nitrosonornicotine and 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone. Carcinogenesis 1989 10 : 1997 2002.
10. Reibel J. Prognosis of oral pre-malignant lesions: significance of clinical, histopathological, and molecular biological characteristics. Crit Rev Oral Biol Med 2003 14 : 47 62.
11. Larsson A, Axell T, Andersson G. Reversibility of snuff dippers' lesion in Swedish moist snuff users: a clinical and histologic follow-up study. J Oral Pathol Med 1991 20 : 258 264.
12. Warnakulasuriya S, Reibel J, Bouquot J, Dabelsteen E. Oral epithelial dysplasia classification systems: predictive value, utility, weaknesses and scope for improvement. J Oral Pathol Med 2008 37 : 127 133.
13. Pande P, Mathur M, Shukla NK, Ralhan R. pRb and p16 protein alterations in human oral tumorigenesis. Oral Oncol 1998 34 : 396 403.
14. Papadimitrakopoulou V, Izzo J, Lippman SM, et al. Frequent inactivation of p16INK4a in oral premalignant lesions. Oncogene 1997 14 : 1799 1803.
15. Bradley KT, Budnick SD, Logani S. Immunohistochemical detection of p16INK4a in dysplastic lesions of the oral cavity. Mod Pathol 2006 19 : 1310 1316.
16. Vairaktaris E, Yapijakis C, Psyrri A, et al. Loss of tumour suppressor p16 expression in initial stages of oral oncogenesis. Anticancer Res 2007 27 : 979 984.
17. Winn DM. Epidemiology of cancer and other systemic effects associated with the use of smokeless tobacco. Adv Dent Res 1997 11 : 313 321.
18. Hoffmann D, Djordjevic MV. Chemical composition and carcinogenicity of smokeless tobacco. Adv Dent Res 1997 11 : 322 329.
19. Rodu B, Jansson C. Smokeless tobacco and oral cancer: a review of the risks and determinants. Crit Rev Oral Biol Med 2004 15 : 252 263.
20. Andersson G. Snuff-induced changes associated with the use of loose and portion-bag-packed Swedish moist snuff. A clinical, histological and follow-up study. Swed Dent J Suppl 1991 75 : 1 89.
21. Blot WJ, McLaughlin JK, Winn DM, et al. Smoking and drinking in relation to oral and pharyngeal cancer. Cancer Res 1988 48 : 3282 3287.
22. Boffetta P, Aagnes B, Weiderpass E, Andersen A. Smokeless tobacco use and risk of cancer of the pancreas and other organs. Int J Cancer 2005 114 : 992 995.
23. Luo J, Ye W, Zendehdel K, et al. Oral use of Swedish moist snuff (snus) and risk for cancer of the mouth, lung, and pancreas in male construction workers: a retrospective cohort study. Lancet 2007 369 : 2015 2020.
24. Schildt EB, Eriksson M, Hardell L, Magnuson A. Oral snuff, smoking habits and alcohol consumption in relation to oral cancer in a Swedish case-control study. Int J Cancer 1998 77 : 341 346.
25. Stockwell HG, Lyman GH. Impact of smoking and smokeless tobacco on the risk of cancer of the head and neck. Head Neck Surg 1986 9 : 104 110.
26. Winn DM, Blot WJ, Shy CM, Pickle LW, Toledo A, Fraumeni JF Jr. Snuff dipping and oral cancer among women in the southern United States. N Engl J Med 1981 304 : 745 749.
27. Kabat GC, Chang CJ, Wynder EL. The role of tobacco, alcohol use, and body mass index in oral and pharyngeal cancer. Int J Epidemiol 1994 23 : 1137 1144.
28. Lewin F, Norell SE, Johansson H, et al. Smoking tobacco, oral snuff, and alcohol in the etiology of squamous cell carcinoma of the head and neck: a population-based case-referent study in Sweden. Cancer 1998 82 : 1367 1375.
29. Foulds J, Ramstrom L, Burke M, Fagerstrom K. Effect of smokeless tobacco (snus) on smoking and public health in Sweden. Tob Control 2003 12 : 349 359.
30. Andersson G, Warfvinge G. The influence of pH and nicotine concentration in oral moist snuff on mucosal changes and salivary pH in Swedish snuff users. Swed Dent J 2003 27 : 67 75.
31. Andersson G, Bjornberg G, Curvall M. Oral mucosal changes and nicotine disposition in users of Swedish smokeless tobacco products: a comparative study. J Oral Pathol Med 1994 23 : 161 167.
32. Hirsch JM, Thilander H. Snuff-induced lesions of the oral mucosa - an experimental model in the rat. J Oral Pathol 1981 10 : 342 353.
33. Djordjevic MV, Fan J, Bush LP, Brunnemann KD, Hoffmann D. Effects of storage on levels of tobacco N-nitrosamine and N-nitrosamino acid in U.S. moist snuff. J Agric Food Chem 1993 41 : 1790 1794.
34. Brunnemann KD, Qi J, Hoffmann D. Chemical profile of two types of oral snuff tobacco. Food Chem Toxicol 2002 40 : 1699 1703.
35. Hong Y, Li C, Xia J, Rhodus NL, Cheng B. Xp16(CDKN2A) expression during rat tongue carcinogenesis induced by 4-Nitroquinoline-1-oxide. Oral Oncol 2009 45 : 640 644.
36. Kanojia D, Vaidya MM. 4-Nitroquinoline-1-oxide induced experimental oral carcinogenesis. Oral Oncol 2006 42 : 655 667.
37. Cowan CG, Gregg TA, Napier SS, McKenna SM, Kee F. Potentially malignant oral lesions in Northern Ireland: a 20-year population-based perspective of malignant transformation. Oral Dis 2001 7 : 18 24.
38. Buajeeb W, Poomsawat S, Punyasingh J, Sanguansin S. Expression of p16 in oral cancer and premalignant lesions. J Oral Pathol Med 2009 38 : 104 108.